<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <link rel="shortcut icon" href="../images/favicon.png" type="image/x-icon">
  <title>Hypertension in Children</title>
  <link href="https://cdn.jsdelivr.net/npm/remixicon@2.5.0/fonts/remixicon.css" rel="stylesheet">
  <link rel="stylesheet" href="../style.css">
  <link rel="stylesheet" href="../notes.css">
</head>
<body>
  <input type="checkbox" id="main-navigation-toggle" class="btn btn--close" title="Toggle main navigation" />
  <label for="main-navigation-toggle">
    <span></span>
  </label>
  
  <a href="../index.html">
   <div class="home-navigation">
      mtr<span class="logo-dot">.</span>
    </div>
  </a>


    <nav id="main-navigation" class="nav-main">
    <ul class="menu">
      <li class="menu__item">
        <a class="menu__link" href="../index.html">Home</a>
      </li>

      <li class="menu__item">
        <a class="menu__link" href="../about-temp2.html">About</a>
      </li>
    </ul>
  </nav>
  
      <!-- Toggle switch for dark mode -->
      <div class="dark-mode-toggle">
        <label class="switch-toggle">
            <input type="checkbox" id="dark-mode-toggle-checkbox">
            <span class="toggle-slider"></span>
        </label>
      </div>

      <!-- Progress Bar  -->
      <div id="progress-container">
        <div id="progress-bar"></div>
    </div>
      
<!-- SIDEBAR -->
<div id="sidebar" class="sidebar">
  <button id="closeSidebarBtn" class="btn toggle-btn close-btn">Close</button>
  <ul class="sidebar-menu toggle-menu">
    <!-- Add the list of topics dynamically using JavaScript -->
  </ul>
</div>

<!-- Toggle button to open the sidebar -->
<button id="toggleSidebarBtn" class="btn toggle-btn">&#9776;</button>

<!-- END OF SIDEBAR -->

  <main class="page-container">
    <div class="contribute-cta">
      <p>Help make this betterüíú</p>
      <span><a href="../contribute.html">Contribute here</a> </span>
    </div>

    <h1>Hypertension in Children</h1>
  
    <!-- <div class="author-flex">
      <div class="author-img">
        <img  src="/contributors/vt1.jpeg" alt="">
      </div>
      <div>
        <h2 class="name">Compiled by Victortayo</h2>
        <p class="updated">last updated</p>
      </div>
    </div> -->

    <article class="notes">
      <a id='top'></a>
  <article>

        <!-- LEARNING OBJECTIVES CONTAINER  -->
            <div class="custom-card" id="custom-card-1">
              <div class="icon"><img src="../images/icons/light-bulb.png" alt="Icon" class="icon"></div>
              <div class="title"> 
                <h2>What You Will Learn</h2>
              </div>
              <div class="line">
                <p>After reading this note, you should be able to...</p>
              </div>
              <div class="content">
                <ul>
                  <li><i>This content is not available yet.</i></li>
              </ul>
              </div>
              <div class="read-more" onclick="toggleContent('custom-card-1')">Read More üç™</div>
            </div>
          
        <!-- END OF LEARNING OBJECTIVES CONTAINER  -->
      
      
        <!-- SHOW AND HIDE OUTLINE CONTAINER  -->
          <div class="outline2">
      
            <input type="radio" name="control-2" id="show-2">
            <label for="show-2">üêµ&nbsp; &nbsp;Show Outline</label>
            <input type="radio" name="control-2" id="hide-2">
            <label for="hide-2">üôà&nbsp; &nbsp; Hide Outline</label>
            <div class="contents">
              <div class="icon-box">
                <!-- Replace 'path/to/your/icon.png' with the actual path to your PNG icon -->
                <img src="../images/icons/book.png" alt="Icon" class="icon">
              </div>
              <div id="tableOfContents">
                  <ol id="tocList"></ol>
              </div>
            </div>
           <div>
      
      <!-- END OF SHOW AND HIDE OUTLINE CONTAINER  -->

      <br>

      <section id='header-1'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-1'>Introduction</a>
          </h2>
        </header>
        <div class='body'>
            <h4>Background</h4>
            <p>In the mid-1970s, the National High Blood Pressure Education Program (NHBPEP) of the National Heart, Lung, and Blood Institute (NHLBI) examined the available blood pressure distribution in healthy children and defined the upper limit of normal blood pressure in children.</p>
            
            <p>The report, known as the first report, was published in 1977.</p>
            
            <p>Major updates of this report were conducted in 1987, 1996, and 2004; these updates are referred to as the second, third, and fourth reports, respectively.</p>
            
            <p>In 2017, the AAP supported the development and published new clinical practice guidelines for hypertension in children, referred to as the fifth report, using recommendations from the Institute of Medicine.</p>
            

            <h4>Definition of Terms</h4>

            <p><strong>Hypertension</strong> is defined as Systolic and/or Diastolic Blood Pressure ‚â• 95th percentile for age, sex, and height or Systolic Blood Pressure ‚â• 130/80 mmHg for children above 13 years of age on three or more occasions.</p>
            
            <p><strong>White coat hypertension (WCH)</strong> is a condition where blood pressure in the clinic setting is high while the BP during Ambulatory Blood Pressure Measurement is normal. This occurs due to a pressor response in the medical setting.</p>
            
            <p><strong>Masked HTN (MH)</strong> is characterized by high Ambulatory BP in the presence of normal Blood Pressure in the clinic. Previously referred to as ‚Äúreverse WCH‚Äù or ‚ÄúWC normotension,‚Äù Masked Hypertension has been associated with more extensive target organ damage than is seen in true normotensive subjects.</p>
            
            <p><strong>Ambulatory Blood Pressure Measurement (ABP)</strong> is a 24-hour Blood Pressure Measurement with two-hourly measurements recorded. It assesses diurnal variation in blood pressure and is considered more reliable than other methods. Values based on ABP correlate better with organ damage.</p>
            

            <div class="image-container">
                <img src="../figures/" alt="" onclick="openModal(this)">
                <div class="caption"></div>
              </div>
              
              <div id="myModal" class="modal">
                <span class="close" onclick="closeModal()">&times;</span>
                <img class="modal-content" id="modalImage">
                <div id="caption" class="caption"></div>
              </div>

              <div class="image-container">
                <img src="../figures/" alt="" onclick="openModal(this)">
                <div class="caption"></div>
              </div>
              
              <div id="myModal" class="modal">
                <span class="close" onclick="closeModal()">&times;</span>
                <img class="modal-content" id="modalImage">
                <div id="caption" class="caption"></div>
              </div>


        </div>

      </section>

      <section id='header-2'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-2'>Epidemiology</a>
          </h2>
        </header>
        <div class='body'>
            <ul>
              <li><strong>Hypertension prevalence:</strong> Uncommon in infants and younger children (ÀÇ 1%).</li>
              <li><strong>Severe symptomatic Hypertension:</strong> Usually secondary.</li>
              <li><strong>Rising prevalence:</strong> Linked to increasing rates of obesity.</li>
              <li><strong>Global prevalence (1994 ‚Äì 2018):</strong> 4% in those 19 years and younger.</li>
              <li><strong>Age-specific prevalence:</strong> Ranging from 3.28% (age 19) to 7.89% (age 14).</li>
              <li><strong>Africa prevalence (1996 ‚Äì 2017):</strong> Overall 5.5%, with regional variations.</li>
              <li><strong>Regional prevalence:</strong> Central (9.8% - 10.1%), Eastern (6.5% - 17.1%), Northern (4.8% - 19.7%), Southern (4.5% - 21.2%), Western (0.2% - 24.8%).</li>
              <li><strong>Relationship with BMI:</strong> Notable BP increase with higher BMI.</li>
              <li><strong>Nigeria prevalence:</strong> Ranged from 2.3% to 10.2% across the country.</li>
              <li><strong>Zaria prevalence (2005):</strong> 2.8% (Bugaje et al.).</li>
            </ul>
            
            <h4>Determinants of Hypertension</h4>

            <ul>
              <li>Age</li>
              <li>Height</li>
              <li>Gender</li>
              <li>Race</li>
              <li>Birth weight</li>
              <li>Nephron number</li>
              <li>Lifestyle</li>
              <li>Obesity</li>
              <li>Salt intake</li>
              <li>Calcium and potassium supplementation</li>
              <li>Sleep-disordered breathing</li>
            </ul>
            

        </div>
      </section>

      <section id='header-3'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-3'>Aetiology</a>
          </h2>
        </header>
        <div class='body'>
            <p>Hypertension can be classified as either primary, with no identifiable cause, or secondary, where an underlying cause is identified.</p>
            
            <p>Most cases of secondary hypertension result from pathologies in other organs, which can include:</p>
            
            <ol>
              <li>Kidneys and their vessels</li>
              <li>Adrenal glands</li>
              <li>Thyroid gland</li>
              <li>Heart</li>
            </ol>
            

            <h4>Causes of Hypertension in Children</h4>

            <h4>Renal</h4>
            <ul>
              <li>Renal parenchymal disease</li>
              <li>Renal vascular disease</li>
            </ul>
            
            <h4>Cardiovascular</h4>
            <ul>
              <li>Coarctation of the Aorta</li>
              <li>Conditions with large stroke volume (PDA, AV Fistula)</li>
            </ul>
            
            <h4>Endocrine</h4>
            <ul>
              <li>Hyperthyroidism</li>
              <li>Excessive catecholamines (Pheochromocytoma)</li>
              <li>Adrenal Dysfunction (CAH 11B, 17A hydroxylase deficiency, Cushing Syndrome), Obesity</li>
              <li>Hyperaldosteronism (Conn‚Äôs, Renin-producing tumors)</li>
              <li>Hyperparathyroidism</li>
            </ul>
            
            <h4>Neurogenic</h4>
            <ul>
              <li>Raised ICP (Intracranial Pressure)</li>
            </ul>
            
            <h4>Drugs/Chemicals</h4>
            <ul>
              <li>Sympathomimetics</li>
              <li>Steroids</li>
              <li>Amphetamines</li>
              <li>Lead</li>
            </ul>
            
            <h4>Miscellaneous</h4>
            <ul>
              <li>Hypercalcemia</li>
            </ul>
            
            <h4>Common causes of childhood Hypertension by age group</h4>
            
            <table class="note-table">
              <thead>
                <tr>
                  <th>Age Group</th>
                  <th>Causes</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td>Neonates</td>
                  <td>Renal Vein Thrombosis, Umbilical Artery Catheterization</td>
                </tr>
                <tr>
                  <td>Children</td>
                  <td>Renal disease, Coarctation of Aorta, Endocrine diseases, Drugs</td>
                </tr>
                <tr>
                  <td>Adolescents</td>
                  <td>Essential Hypertension</td>
                </tr>
              </tbody>
            </table>
            
        </div>
      </section>

      <section id='header-4'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-4'>Measurement of Blood Pressure (BP)</a>
          </h2>
        </header>
        <div class='body'>
            <p><strong>Appropriate Cuff Size:</strong></p>
            <ul>
              <li>The cuff bladder length should be between 80% and 100% of the arm circumference.</li>
              <li>The width of the cuff should be 40% of the arm circumference, measured at the midpoint between the acromion and olecranon.</li>
            </ul>
            
            <p><strong>Procedure:</strong></p>
            <ul>
              <li>Inflate the cuff to a pressure 20‚Äì30 mm Hg above the point where the radial pulse disappears. Avoid overinflation.</li>
              <li>Deflate the cuff at a rate of 2‚Äì3 mmHg per second.</li>
              <li>Record the first audible sound (phase I Korotkoff) as the Systolic Blood Pressure (SBP).</li>
              <li>Record the last audible sound (phase V Korotkoff) as the Diastolic Blood Pressure (DBP).</li>
            </ul>
            
            <p>Measurements should be rounded to the nearest 2 mmHg.</p>
            
            <div class="image-container">
                <img src="../figures/" alt="" onclick="openModal(this)">
                <div class="caption"></div>
              </div>
              
              <div id="myModal" class="modal">
                <span class="close" onclick="closeModal()">&times;</span>
                <img class="modal-content" id="modalImage">
                <div id="caption" class="caption"></div>
              </div>

              <h4>Blood Pressure Check Recommendations</h4>

              <p><strong>Fifth Report (Latest Recommendation):</strong></p>
              <p>An annual blood pressure check is recommended for otherwise healthy children above 3 years of age.</p>
              
              <p><strong>Fourth Report:</strong></p>
              <p>In the fourth report, blood pressure checks were recommended for children 3 years of age and older at all healthcare encounters, including well-child care or sick visits.</p>
              
              <p>Additionally, certain children younger than 3 years with comorbid conditions should also have their blood pressure monitored. These conditions include:</p>
              
              <ul>
                <li>Prematurity</li>
                <li>Low birth weight (LBW) infants</li>
                <li>Congenital heart or genitourinary anomalies</li>
                <li>Recurrent urinary tract infections (UTI)</li>
                <li>Hematuria or proteinuria</li>
                <li>Malignancy</li>
                <li>Certain medications</li>
                <li>Systemic illness associated with hypertension</li>
              </ul>
              

        </div>
      </section>

      <section id='header-5'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-5'>Evaluation</a>
          </h2>
        </header>
        <div class='body'>
            <p><strong>Basic Evaluation:</strong></p>
            <ul>
              <li>Serum electrolyte, urea, creatinine</li>
              <li>Full blood count</li>
              <li>Urinalysis and Urine culture</li>
              <li>Renal ultrasound with Doppler</li>
            </ul>
            
            <p><strong>Evaluation for Comorbidity:</strong></p>
            <ul>
              <li>Fasting Lipid profile</li>
              <li>Fasting glucose</li>
            </ul>
            
            <p><strong>Evaluation for End-Organ Damage:</strong></p>
            <ul>
              <li>Echocardiogram</li>
              <li>Retinal exam</li>
            </ul>
            
        </div>
      </section>

      <section id='header-6'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-6'>Treatment</a>
          </h2>
        </header>
        <div class='body'>
            <p><strong>Goals of Treatment</strong></p>
            
            <p><strong>General:</strong></p>
            <ul>
              <li>Blood pressure less than the 90th percentile for age, sex, and height</li>
              <li>Or</li>
              <li>Blood pressure less than 130/80 mmHg</li>
              <li>Whichever is lower of the above based on office/casual BP reading.</li>
            </ul>
            
            <p><strong>For patients with CKD:</strong></p>
            <ul>
              <li>Ambulatory Blood Pressure Monitoring (ABPM) is recommended</li>
              <li>A 24-hour Mean Arterial Pressure (MAP) less than the 50th percentile is recommended.</li>
            </ul>
            
            <p><strong>Non-pharmacological Treatment</strong></p>
            <ul>
              <li>Weight reduction.</li>
              <li>Regular physical activity.</li>
              <li>Dietary modification</li>
            </ul>
            
            <p><strong>DASH diet:</strong> consumption of more fruits, vegetables, fiber, non-fat dairy, reduced sodium intake (1.2g/day in younger children and 1.5g/day in older children)</p>

            <h4>General Guidelines to Pharmacotherapy</h4>

            <p><strong>Indications:</strong></p>
            <ol>
              <li>Persistent hypertension despite lifestyle modifications, especially with an abnormal echocardiogram; Symptomatic hypertension</li>
              <li>Stage 2 hypertension without a modifiable risk factor</li>
              <li>Any stage of hypertension in patients with diabetes mellitus or CKD</li>
            </ol>
            
            <p><strong>Principles:</strong></p>
            <ol>
              <li>Monotherapy is advocated at inception using the lower dose range.</li>
              <li>The dose could be increased in a step-wise manner until the maximum tolerable dose</li>
              <li>Initial agent could be replaced with a member from another class.</li>
              <li>Another agent that has complementary action could be added because of additive effect and the need to reduce the chances of evolution of dose-dependent adverse effect.</li>
            </ol>
            
            <h4>Recommended doses for selected Antihypertensive agents in children and adolescents</h4>

            <table class="note-table">
              <tr>
                <th>Class</th>
                <th>Drug</th>
                <th>Dose</th>
                <th>Maximum Dose</th>
              </tr>
              <tr>
                <td>Aldosterone Receptor Antagonist</td>
                <td>Spironolactone</td>
                <td>1 mg/kg/day qd-bid</td>
                <td>100 mg/day</td>
              </tr>
              <tr>
                <td rowspan="2">ACE Inhibitors</td>
                <td>Captopril</td>
                <td>0.5 mg/kg/day (0.05 mg/kg/dose in infants) tid</td>
                <td>450 mg/day</td>
              </tr>
              <tr>
                <td>Lisinopril</td>
                <td>0.07 mg/kg/day qd</td>
                <td>40 mg/day</td>
              </tr>
              <tr>
                <td>ARB</td>
                <td>Losartan</td>
                <td>0.75 mg/kg/day qd</td>
                <td>100 mg/day</td>
              </tr>
              <tr>
                <td rowspan="2">Alpha and Beta-Adrenergic Blockers</td>
                <td>Labetalol</td>
                <td>2-3 mg/kg/day bid</td>
                <td>1.2 g/day</td>
              </tr>
              <tr>
                <td>Carvedilol</td>
                <td>0.1 mg/kg/dose bid</td>
                <td>25 mg bid</td>
              </tr>
              <tr>
                <td rowspan="2">Beta-Adrenergic Antagonists</td>
                <td>Atenolol</td>
                <td>0.5-1 mg/kg/day qd-bid</td>
                <td>100 mg/day</td>
              </tr>
              <tr>
                <td>Propranolol</td>
                <td>1 mg/kg/day bid-tid</td>
                <td>640 mg/day</td>
              </tr>
              <tr>
                <td>Calcium Channel Blockers</td>
                <td>Amlodipine</td>
                <td>1-5 years: 0.1 mg/kg/day; &gt;6 years: 2.5 mg/day qd</td>
                <td>1-5 years: 5 mg/day &gt;6 years: 10 mg/day</td>
              </tr>
              <tr>
                <td>Central Alpha Agonist</td>
                <td>Clonidine</td>
                <td>5-10 Œºg/kg/day bid-tid</td>
                <td>0.9 mg/day</td>
              </tr>
              <tr>
                <td rowspan="2">Diuretics</td>
                <td>Furosemide</td>
                <td>0.5-2.0 mg/kg/day qd-bid</td>
                <td>6 mg/day</td>
              </tr>
              <tr>
                <td>HCTZ (Hydrochlorothiazide)</td>
                <td>0.5-1 mg/kg/day qd</td>
                <td>37.5 mg/day</td>
              </tr>
              <tr>
                <td rowspan="2">Vasodilators</td>
                <td>Hydralazine</td>
                <td>0.25 mg/kg/dose tid-qid</td>
                <td>200 mg/day</td>
              </tr>
              <tr>
                <td>Minoxidil</td>
                <td>0.1-2 mg/kg/day bid-tid</td>
                <td>50 mg/day</td>
              </tr>
            </table>

            <h4>Antihypertensives used for severely hypertensive patients with less significant symptoms</h4>

            <table class="note-table">
              <tr>
                <th>Class</th>
                <th>Drug</th>
                <th>Dose</th>
                <th>Route</th>
                <th>Remarks</th>
              </tr>
              <tr>
                <td>Central Agonist</td>
                <td>Clonidine</td>
                <td>0.05-1.0 mg/dose, may be repeated up to 0.8 mg total dose</td>
                <td>PO</td>
                <td>Side effects include dry mouth and drowsiness</td>
              </tr>
              <tr>
                <td rowspan="2">Direct Vasodilator</td>
                <td>Hydralazine</td>
                <td>0.25 mg/kg/dose, up to 25 mg/dose</td>
                <td>PO</td>
                <td>Extemporaneous suspension stable only for a week</td>
              </tr>
              <tr>
                <td>Minoxidil</td>
                <td>0.1-0.2 mg/kg/dose, up to 10 mg/dose</td>
                <td>PO</td>
                <td>Most potent vasodilator; long-acting</td>
              </tr>
              <tr>
                <td>Dopamine Agonist</td>
                <td>Fenoldopam</td>
                <td>0.2-0.8 Œºg/kg/min</td>
                <td>IV infusion</td>
                <td>Modest reduction in blood pressure in pediatric age group</td>
              </tr>
              <tr>
                <td>Calcium Channel Blocker</td>
                <td>Isradipine</td>
                <td>0.05-0.15 mg/kg/dose, up to 5 mg/dose</td>
                <td>PO</td>
                <td>Stable suspension, can be compounded</td>
              </tr>
            </table>
            

            <h4>Antihypertensives for Severely Hypertensive Patients with Life-Threatening Symptoms</h4>

            <table class="note-table">
              <tr>
                <th>Class</th>
                <th>Drug</th>
                <th>Dose</th>
                <th>Route</th>
                <th>Remarks</th>
              </tr>
              <tr>
                <td>Beta-Adrenergic Blocker</td>
                <td>Esmolol</td>
                <td>100-500 Œºg/kg/min</td>
                <td>IV infusion</td>
                <td>Very short-acting, may cause profound bradycardia</td>
              </tr>
              <tr>
                <td rowspan="2">Direct Vasodilator</td>
                <td>Hydralazine</td>
                <td>0.2-0.4 mg/kg/dose</td>
                <td>IV, IM</td>
                <td>Given every 4 hours if bolus</td>
              </tr>
              <tr>
                <td>Sodium Nitroprusside</td>
                <td>0.5-10 Œºg/kg/min</td>
                <td>IV infusion</td>
                <td>Monitor levels if given for >72 hours or in renal failure</td>
              </tr>
              <tr>
                <td>Alpha- and Beta-Adrenergic Blocker</td>
                <td>Labetalol</td>
                <td>Bolus: 0.2-1 mg/kg/dose, up to 40 mg/dose<br>Infusion: 0.25-3.0 mg/kg/hr</td>
                <td>IV bolus or Infusion</td>
                <td>Asthma and overt heart failure are contraindications</td>
              </tr>
              <tr>
                <td>Calcium Channel Blocker</td>
                <td>Nicardipine</td>
                <td>Bolus: 30 Œºg/kg, up to 2 mg/dose<br>Infusion: 0.5-4 Œºg/kg/min</td>
                <td>IV bolus or Infusion</td>
                <td>May cause reflex tachycardia</td>
              </tr>
            </table>
            
            
        </div>
      </section>

      <section id='header-7'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-7'> Complications</a>
          </h2>
        </header>
        <div class='body'>

            <h4>Hypertensive Emergency</h4>
            
            <p>
              A spectrum of clinical presentation where uncontrolled BP leads to end-organ dysfunction with BP elevation ‚â• 30 mmHg above the 95th percentile. Examples include CVA (Cerebrovascular Accident), AKI (Acute Kidney Injury), LVD (Left Ventricular Dysfunction), retinopathy, malignant hypertension.
            </p>
            
            <p><strong>Treatment:</strong> Admit to the ICU!</p>
            
            <ul>
              <li>BP should be lowered aggressively over minutes to hours.</li>
              <li>Reduce BP by 25-30% in the first 8 hours, then to normal in the next 24 - 48 hours.</li>
              <li>Precipitous drop in BP can result in impairment of perfusion of vital organs.</li>
              <li>Use parenteral very short-acting antihypertensives.</li>
            </ul>
            
            <h4>Monitoring/Follow-Up</h4>
            
            <p>
              Patients treated with drugs should have follow-up every 4 ‚Äì 6 weeks for dose adjustments until the target BP is achieved, then 3 ‚Äì 4 monthly follow-up visits.
            </p>
            
            <p>
              Those on lifestyle modification only should have 3 ‚Äì 6 monthly visits.
            </p>
            
        </div>
      </section>

      <section id='header-8'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-8'> Summary</a>
          </h2>
        </header>
        <div class='body'>
            <p>
              The major points of the 2017 AAP CPG are:
            </p>
            
            <ul>
              <li>Change in HTN categorization</li>
              <li>Revised BP tables and screening tables</li>
              <li>Use of ABPM</li>
              <li>Lower treatment goals</li>
            </ul>
            
            <p>
              The cutoff point for hypertension in children and adolescents is lower than the previous cutoff points in the fourth report. The new guideline is based on evidence-based data, excluding children who are overweight and obese.
            </p>
            
            <p>
              Emphasis is placed on 24-hour ABPM as a way to diagnose children and adolescents with masked hypertension, which is associated with target organ damage. It is also useful for monitoring BP in children with CKD.
            </p>
            
            <p>
              Except in children with co-morbidities and underlying conditions with an increased risk of hypertension, monitoring of blood pressure in otherwise well children greater than 3 years should be done annually.
            </p>
            
            <p>
              The goal of treatment is to attain lower blood pressure levels for all hypertensives, with even lower values for those with CKD. Monotherapy, rather than multi-drug therapy, is advocated, and doses should be increased in a step-wise approach until the target BP is attained.
            </p>
            
            <p>
              Echocardiography is only recommended when drug therapy is being considered and not routinely in all hypertensive children or adolescents.
            </p>
            
        </div>
      </section>

      <section id='header-9'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-9'>Conclusion </a>
          </h2>
        </header>
        <div class='body'>
            <p>
              Hypertension is a silent killer; hence, early diagnosis and the institution of appropriate management can significantly prevent morbidity and mortality. More pertinent is the prevention of hypertension through lifestyle modification, particularly for those with risk factors for hypertension.
            </p>
            
            <p>
              The 2017 AAP CPG addresses aspects of the evaluation and management of high BP in children and adolescents based on a strict evidence-based approach, as recommended by the NHLBI. It is the first to be aligned as much as possible with the new guidelines for adults.
            </p>
            
        </div>
      </section>




      <hr style="margin: 3rem 0;">

      <!-- PRACTICE QUESTIONS CONTAINER -->

      <div class="custom-card" id="custom-card-2">
        <div class="icon"><img src="../images/icons/practice-questions.png" alt="Icon" class="icon"></div>
        <div class="title"> 
          <h2>Practice Questions</h2>
        </div>
        <div class="line">
          <p>Check how well you grasp the concepts by answering the following questions...</p>
        </div>
        <div class="content">
          <ol>
            <li><i>This content is not available yet.</i></li>
          </ol>
        </div>
        <div class="read-more" onclick="toggleContent('custom-card-2')">Read More üç™</div>
      </div>

      <!-- END OF PRACTICE QUESTIONS CONTAINER -->


      <!-- CONTACT- COMMENT AND CONTRIBUTORS CONTAINER -->
      <div class="contact">
        <div class="comment-container">
          <div class="comment-icon">
            <!-- Add your icon image here -->
            <img src="../images/icons/comment.png" alt="Comment Icon">
          </div>
          <div class="comment-text">
            <!-- Add your text here -->
            <p>Send your comments, corrections, explanations/clarifications and requests/suggestions </p>
          </div>
          <a href="https://docs.google.com/forms/d/e/1FAIpQLSdx2teDCmW6ivSeKLQg7zF_jy7Yfg_1Gqm84_UT0PQPATsNug/viewform?usp=sf_link" class="comment-button">
            here
            <!-- <img src="../images/icons/whatsapp.png" alt="Image Icon"> -->
          </a>
        </div>


      </div>

            <!-- END OF CONTACT- COMMENT AND CONTRIBUTORS CONTAINER -->
    </article>
   </article>
   <div style="height: 300px;"></div>
  </main>

  <footer>
    <div class="footer-container">
        <div>
          <p id="popup-trigger">disclaimer</p>

          <!-- The pop-up dive content -->
          <div id="popup" class="popup">
            <p>The contents on this ‚Äòwebsite‚Äô are for educational purposes only. The creators and operators of this website make no warranties, express or implied, regarding the accuracy, currency, or completeness of the information provided on the website. They shall not be held responsible for any errors or omissions, or for any actions taken based on the information provided on this website.</p>
            <button class="popup-close" onclick="closePopup()">Close</button>
          </div>    
          <p><a href="../about-temp2.html">about</a> </p>   
          <p><a href="../contribute.html">contribute</a> </p>
        </div>

        <div class="footer-beta">
          <p>thisisatestversion</p>
        </div>
    </div>
  </footer>
<!------------  SCROLL UP ----------->
<a href="#" class="scrollup" id="scroll-up"> 
  <i class="ri-arrow-up-fill scrollup__icon"></i>
</a>
<script src="../main.js"></script>
<script src="../modal.js"></script>
<script src="../notes-sidebar.js"></script>
</body>
</html>
 
 
